

Sensitivity and Specificity of Anti- α -Fodrin Antibodies in Primary Sjögren's Syndrome

To the Editor:

We read with interest the report by Ruffatti, *et al*¹, whose results correspond to our recent findings suggesting a low sensitivity and a high specificity of IgA and IgG-type anti- α -fodrin antibodies.

In 1998, at the Department of Clinical Immunology, University of Debrecen, we investigated anti- α -fodrin antibodies in 67 patients with primary Sjögren's syndrome (SS), 20 with rheumatoid arthritis (RA), 21 with systemic lupus erythematosus (SLE), 20 with secondary SS associated with RA, and 17 with secondary SS associated with SLE, and in 30 healthy blood donors. Autoantibodies against class IgA and IgG-type α -fodrin were detected by the same commercial ELISA kit used by Ruffatti, *et al*. In the year 1998, European Community Study Group criteria² were used to diagnose SS. The sensitivity for IgA and IgG anti- α -fodrin for SS was 37.3% and 38.8%, respectively. The specificity was 93.3% for both isotypes³.

In 2003, we repeated the measurement of anti- α -fodrin in the sera of 46 patients with SS and healthy blood donors, using the American-European Consensus criteria⁴ for SS and using the same ELISA kit for detection of antibodies. The sensitivity for IgA and IgG anti- α -fodrin was 17.3% and 28.2%, the specificity 93.3% and 100%, respectively.

Similarly to Ruffatti, *et al* we also concluded that the antibodies against anti- α -fodrin are not sufficiently sensitive for diagnostic markers for SS, especially after the diagnostic criteria have been made more rigorous. Interestingly, we did find correlation between the presence of anti-SSA and IgG-type anti- α -fodrin autoantibodies, and we suggest using anti- α -fodrin autoantibodies in screening patients followed serologically and clinically for early diagnosis of SS.

ANTÓNIA SZÁNTÓ, MD; ISTVÁN CSÍPO, PhD; MARGIT ZEHER, MD, PhD, Division of Clinical Immunology, Medical and Health Science Center, University of Debrecen, Móricz Zs. Krt. 22, H-4004 Debrecen, Hungary. Address reprint requests to Dr. Szántó: szantonia@freemail.hu

REFERENCES

1. Ruffatti A, Ostuni P, Grypiotis P, et al. Sensitivity and specificity for primary Sjögren's syndrome of IgA and IgG anti- α -fodrin antibodies detected by ELISA. *J Rheumatol* 2004;31:504-7.
2. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. *Arthritis Rheum* 1993;36:340-7.
3. Szanto A, Csipo I, Zeher M. Prevalence of anti- α -fodrin autoantibodies in our patients with Sjögren's syndrome [Hungarian]. *Hungarian Immunology* 2003;2:40-4.
4. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.

Dr. Ruffatti, *et al* reply

To the Editor:

We thank Dr. Szántó and colleagues for their interest in our article¹. The results they report² confirm low sensitivity of IgA and IgG anti- α -fodrin antibodies for primary Sjögren's syndrome (SS) using ELISA. Indeed, we found a similar low prevalence for both IgA and IgG anti- α -fodrin antibodies in primary SS sera: 32.5% vs 37.3% and 21.1% vs 38.8%, respectively. These findings are in keeping with other recent studies^{3,4}, which appeared while our report was being evaluated for publication, that reported a low fre-

quency of anti- α -fodrin antibodies in primary SS patients on the basis of various techniques including immunoprecipitation, immunoblotting, and ELISA. On the other hand, we observed specificity of both IgA and IgG anti- α -fodrin antibodies lower than that reported by Szántó, *et al*²: 68.1% versus 93.3% and 79% versus 93.3%, respectively. This difference could be due to a variation in the number of control subjects. Moreover, the specificity of anti- α -fodrin antibodies for primary SS presently is debatable, probably because the numbers of patients with connective tissue diseases reported in the control groups were not homogeneous¹⁻⁴.

Most studies showing a high prevalence of anti- α -fodrin antibodies in primary SS⁵⁻⁸ utilized the European Community Study Group criteria⁹ for classification. Using the same criteria we observed a low prevalence of anti- α -fodrin antibodies in patients with primary SS, in agreement with Szántó, *et al*. When antibody frequency in primary SS patients classified according to the European criteria was compared with that in patients classified according to the San Diego criteria¹⁰ a higher antibody prevalence was found in the latter group^{3,11}. The difference, however, was statistically significant in only one of the 2 studies¹¹. According to Szántó, *et al*, a low prevalence of IgA and IgG anti- α -fodrin antibodies was recently reported⁴ in primary SS patients meeting the American/European Consensus criteria¹².

Due to the low sensitivity of anti- α -fodrin antibodies confirmed by recent reports²⁻⁴ and by our experience¹, we are doubtful about the use of these antibodies as a diagnostic marker. On the basis of Ulbricht's study¹³ describing normalization of anti- α -fodrin antibodies after 3 months of successful therapy and a correlation between antibody concentration and the degree of lymphocytic infiltration in the salivary glands, it remains to be seen if anti- α -fodrin antibodies may be considered an early marker for disease activity of primary SS.

AMELIA RUFFATTI, MD, Associate Professor of Rheumatology; PANAGIOTIS GRYPLOTIS, PhD, Research Biologist; PIERANTONIO OSTUNI, MD, Assistant Professor of Rheumatology, Department of Medical and Surgical Sciences, Rheumatology Unit, University of Padova, Via Giustiniani 2, 35128 Padova, Italy. Address reprint requests to Dr. Ruffatti: E-mail: amelia.ruffatti@unipd.it

REFERENCES

1. Ruffatti A, Ostuni P, Grypiotis P, et al. Sensitivity and specificity for primary Sjögren's syndrome of IgA and IgG anti- α -fodrin antibodies detected by ELISA. *J Rheumatol* 2004;31:504-7.
2. Szanto A, Csipo I, Zeher M. Prevalence of anti- α -fodrin autoantibodies in our patients with Sjögren's syndrome [Hungarian]. *Hungarian Immunology* 2003;2:40-4.
3. Nordmark G, Rorsman F, Rönnblom L, et al. Autoantibodies to α -fodrin in primary Sjögren's syndrome and SLE detected by an in vitro transcription and translation assay. *Clin Exp Rheumatol* 2003;21:49-56.
4. Zandbelt MM, Vogelzangs J, van de Putte LB, van Venrooij WJ, van den Hoogen FH. Anti- α -fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome. *Arthritis Res Ther* 2004;6:R33-8.
5. Watanabe T, Tsuchida T, Kanda N, Mori K, Hayashi Y, Tamaki K. Anti- α -fodrin antibodies in Sjögren's syndrome and lupus erythematosus. *Arch Dermatol* 1999;135:535-9.
6. Witte T, Matthias T, Arnett FC, et al. IgA and IgG autoantibodies against α -fodrin as marker for Sjögren's syndrome. *J Rheumatol* 2000;27:2617-20.
7. Maeno N, Takei S, Imanaka H, et al. Anti- α -fodrin antibodies in Sjögren's syndrome in children. *J Rheumatol* 2001;28:860-4.
8. Kobayashi I, Kawamura N, Okano M, et al. Anti- α -fodrin autoantibody is an early diagnostic marker for childhood primary Sjögren's syndrome. *J Rheumatol* 2001;28:363-5.
9. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a

- prospective concerted action supported by the European Community. *Arthritis Rheum* 1993;36:340-7.
10. Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren's syndrome. Proposed criteria for classification. *Arthritis Rheum* 1986;29:577-85.
 11. Witte T, Matthias T, Oppermann M, et al. Prevalence of antibodies against α -fodrin in Sjögren's syndrome: comparison of 2 sets of classification criteria. *J Rheumatol* 2003;30:2157-9.
 12. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.
 13. Ulbricht KU, Schmidt RE, Witte T. Antibodies against alpha-fodrin in Sjögren's syndrome. *Autoimmun Rev* 2003;2:109-13.